Press coverage about LeMaitre Vascular (NASDAQ:LMAT) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. LeMaitre Vascular earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the medical instruments supplier an impact score of 45.069116328911 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of LeMaitre Vascular (NASDAQ LMAT) traded down 0.38% on Thursday, reaching $36.40. The company’s stock had a trading volume of 10,803 shares. The stock has a 50 day moving average of $31.97 and a 200-day moving average of $28.18. LeMaitre Vascular has a 12 month low of $16.80 and a 12 month high of $36.80. The firm has a market cap of $692.40 million, a price-to-earnings ratio of 52.00 and a beta of 0.65.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.23 EPS for the quarter, beating the consensus estimate of $0.17 by $0.06. The company had revenue of $25.80 million for the quarter, compared to the consensus estimate of $25.42 million. LeMaitre Vascular had a net margin of 14.19% and a return on equity of 15.02%. The firm’s revenue was up 15.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.14 EPS. On average, analysts anticipate that LeMaitre Vascular will post $0.80 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Wednesday, August 23rd will be issued a dividend of $0.055 per share. The ex-dividend date is Monday, August 21st. This represents a $0.22 annualized dividend and a yield of 0.60%. LeMaitre Vascular’s payout ratio is 31.88%.

LeMaitre Vascular declared that its Board of Directors has approved a share buyback program on Thursday, July 27th that authorizes the company to repurchase $7.50 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to repurchase up to 1.4% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Several research firms recently weighed in on LMAT. Stifel Nicolaus reissued a “buy” rating and set a $32.00 price objective (up previously from $29.00) on shares of LeMaitre Vascular in a report on Sunday, July 30th. Benchmark Co. raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, July 28th. BidaskClub downgraded LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Craig Hallum began coverage on LeMaitre Vascular in a report on Tuesday, June 6th. They set a “hold” rating and a $31.00 price objective on the stock. Finally, Zacks Investment Research downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $30.17.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact LeMaitre Vascular (LMAT) Stock Price” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/31/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-lemaitre-vascular-lmat-stock-price.html.

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 11,300 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $32.79, for a total value of $370,527.00. Following the transaction, the chief executive officer now directly owns 3,405,508 shares in the company, valued at approximately $111,666,607.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO George W. Lemaitre sold 15,000 shares of the company’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $37.13, for a total transaction of $556,950.00. Following the completion of the transaction, the chief executive officer now owns 3,325,508 shares in the company, valued at $123,476,112.04. The disclosure for this sale can be found here. Insiders sold a total of 346,438 shares of company stock worth $11,847,526 over the last 90 days. Insiders own 23.70% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Insider Buying and Selling by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Stock Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related stocks with our FREE daily email newsletter.